Re Agreement

RNS Number:1393M
Tepnel Life Sciences PLC
10 June 2003

FOR IMMEDIATE RELEASE
                                                                   10 June 2003


          Tepnel Life Sciences PLC ('Tepnel') Sells First 'Nucleopure' 
                      Automated DNA Purification System

              New High-Throughput System will Boost Reagent Sales


Manchester, UK. 10 June 2003...Tepnel Life Sciences PLC (AIM: TED) announces
today it has made the first sale to one of the leading UK pharmaceutical
companies of its new 'Nucleopure' automated DNA purification system and
associated reagents. The new system, formerly known as the T2000, automates
Tepnel's Nucleon(R) chemistry and will be used for the extraction, recovery and
purification of high yields of highly intact genomic DNA from a range of
tissues.

Tepnel is expecting further sales of the 'Nucleopure' over the next six months
to other pharmaceutical companies, contract research organisations (CROs) and
biotechnology companies. A growing installed base of 'Nucleopure' systems should
have a significant impact on Tepnel's recurring revenues, given the large
amounts of reagents that are consumed by this new high-throughput system.

Commenting on the announcement, Ben Matzilevich, Tepnel's CEO, said: "We are
very pleased to make this first sale of the 'Nucleopure' system following an
extensive evaluation of the system's capabilities by the customer. This initial
placement provides Tepnel not only with its first instrument sale but also, and
perhaps more importantly, it will generate a significant ongoing revenue stream
in terms of consumables required for the operation of the system. Furthermore,
this sale reinforces Tepnel's strategy of building partnerships with and
providing DNA purification and bioanalytical solutions to companies in the
pharmaceutical industry. We anticipate further sales of 'Nucleopure' systems and
reagents during the remainder of 2003 and beyond."

                                     -ends-

Further enquiries

Tepnel Life Sciences - 0161 946 2200
Ben Matzilevich, CEO
Gron Ffoulkes-Davies, Finance Director

HCC De Facto Group - 020 7496 3300
David Dible / Mark Swallow


Notes to Editors

Tepnel Life Sciences is a global biotechnology company with a "tripolar"
strategy focused on providing the biomedical industry with high-throughput
automated DNA purification systems, manual DNA purification kits and reagents,
as well as scientific services for nucleic acid purification, drug analysis,
genotyping and genetically modified foods (GMOs).

The Company was founded in 1992 to exploit DNA technology generated at UMIST
(University of Manchester Institute of Science and Technology) and is listed on
the AIM segment of the London Stock Exchange (AIM: TED).


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRNKKKPDBKDPAD